程序性死亡因子配体1在肝细胞癌中的表达及意义

Expression of programmed death-ligand 1 in hepatocellular carcinoma and its clinical significance

近年来以阻断PD-1/PD-L1通路为基础的免疫治疗在黑色素瘤、肺癌等恶性肿瘤中取得令人鼓舞的进展,其在肝细胞癌中的研究也在逐渐展开。介绍了PD-1/PD-L1作用机制、肝细胞癌组织中PD-L1的表达情况以及其在肝细胞癌治疗领域的基础及临床研究。认为PD-L1在肿瘤免疫逃逸中发挥重要作用,有望成为判断肝细胞癌预后的独立指标,PD-1/PD-L1通路的发现为肝细胞癌的免疫治疗提供了新的靶点。

In recent years,the immunotherapy based on the blocking of programmed death- 1（ PD- 1） / programmed death- ligand 1（ PD- L1）pathway has achieved encouraging progress in the treatment of malignant tumors such as melanoma and lung cancer. More and more studies have focused on its role in hepatocellular carcinoma（ HCC）. This article introduces the mechanism of action of PD- 1 / PD- L1,expression of PD- L1 in HCC tissues,and its basic and clinical research in the treatment of HCC,and points out that PD- L1 plays an important role in tumor immune escape and is expected to become an independent index for evaluating the prognosis of HCC. The discovery of PD- 1 / PD- L1 pathway provides a new target for immunotherapy for HCC.